Clinical trial
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for…
NCT00433407 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00433407 |
|---|---|
| Title | T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors |
| Official title | A Study to Assess HER2-Specific T Cell Responses in Patients Receiving Trastuzumab for Solid Tumor Treatment |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | trastuzumab |
| Enrollment | 12 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2006 |
| First posted | Feb 12, 2007 |
| Last update posted | Oct 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: